Floatz logo

Cytarabine

Stiff-Person Syndrome

Explore 7 assets in Stiff-Person Syndrome →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Fred Hutchinson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.

No trial-level evidence is linked to this axis yet.

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Stiff-Person Syndrome

AssetSponsorPhaseRating
Cytarabine (this asset)Fred Hutchinson Cancer CenterP2CCC · 53
PrednisoneFred Hutchinson Cancer CenterP2CCC
CamustineFred Hutchinson Cancer CenterP2CCC
MelphalanFred Hutchinson Cancer CenterP2CCC
Anti-Human T-Lymphocyte Immunoglobulin, RabbitFred Hutchinson Cancer CenterP2CCC
EtoposideFred Hutchinson Cancer CenterP2CCC
Kyv-101Kyverna TherapeuticsUnkD

Other indications for Cytarabine

IndicationSponsorPhaseRating
Acute Promyelocytic Leukemia—P4A · 82
Adult Acute Lymphoblastic Leukemia—P4BBB · 79
Acute Myeloblastic Leukemia With Maturation—P3BBB · 78

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Cytarabine in Stiff-Person Syndrome. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/cytarabine-stiff-person-syndrome

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →